A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes

Linda A. Barbour, Christina Scifres, Amy M. Valent, Jacob E. Friedman, Thomas A. Buchanan, Donald Coustan, Kjersti Aagaard, Kent L. Thornburg, Patrick M. Catalano, Henry L. Galan, William W. Hay, Antonio E. Frias, Kartik Shankar, Rebecca A. Simmons, Robert G. Moses, David A. Sacks, Mary R. Loeken

Research output: Contribution to journalArticle

  • 2 Citations

Abstract

Use of oral agents to treat gestational diabetes mellitus remains controversial. Recent recommendations from the Society for Maternal-Fetal Medicine assert that metformin may be a safe first-line alternative to insulin for gestational diabetes mellitus treatment and preferable to glyburide. However, several issues should give pause to the widespread adoption of metformin use during pregnancy. Fetal concentrations of metformin are equal to maternal, and metformin can inhibit growth, suppress mitochondrial respiration, have epigenetic modifications on gene expression, mimic fetal nutrient restriction, and alter postnatal gluconeogenic responses. Because both the placenta and fetus express metformin transporters and exhibit high mitochondrial activity, these properties raise important questions about developmental programming of metabolic disease in offspring. Animal studies have demonstrated that prenatal metformin exposure results in adverse long-term outcomes on body weight and metabolism. Two recent clinical randomized controlled trials in women with gestational diabetes mellitus or polycystic ovary syndrome provide evidence that metformin exposure in utero may produce a metabolic phenotype that increases childhood weight or obesity. These developmental programming effects challenge the conclusion that metformin is equivalent to insulin. Although the Society for Maternal-Fetal Medicine statement endorsed metformin over glyburide if oral agents are used, there are few studies directly comparing the 2 agents and it is not clear that metformin alone is superior to glyburide. Moreover, it should be noted that prior clinical studies have dosed glyburide in a manner inconsistent with its pharmacokinetic properties, resulting in poor glycemic control and high rates of maternal hypoglycemia. We concur with the American Diabetes Association and American Congress of Obstetricians and Gynecologists, which recommend insulin as the preferred agent, but we believe that it is premature to embrace metformin as equivalent to insulin or superior to glyburide. Due to the uncertainty of the long-term metabolic risks of either metformin or glyburide, we call for carefully controlled studies that optimize oral medication dosing according to their pharmacodynamic and pharmacokinetic properties in pregnancy, appropriately target medications based on individual patterns of hyperglycemia, and follow the offspring long-term for metabolic risk.

LanguageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Gestational Diabetes
Metformin
Pharmacology
Glyburide
Insulin
Therapeutics
Pharmacokinetics
Mothers
Pregnancy
Polycystic Ovary Syndrome
Metabolic Diseases
Hypoglycemia
Epigenomics
Hyperglycemia
Placenta
Uncertainty
Respiration
Fetus
Randomized Controlled Trials
Obesity

Keywords

  • diabetes in pregnancy
  • glyburide
  • guidelines
  • metformin

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Barbour, L. A., Scifres, C., Valent, A. M., Friedman, J. E., Buchanan, T. A., Coustan, D., ... Loeken, M. R. (Accepted/In press). A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2018.06.013

A cautionary response to SMFM statement : pharmacological treatment of gestational diabetes. / Barbour, Linda A.; Scifres, Christina; Valent, Amy M.; Friedman, Jacob E.; Buchanan, Thomas A.; Coustan, Donald; Aagaard, Kjersti; Thornburg, Kent L.; Catalano, Patrick M.; Galan, Henry L.; Hay, William W.; Frias, Antonio E.; Shankar, Kartik; Simmons, Rebecca A.; Moses, Robert G.; Sacks, David A.; Loeken, Mary R.

In: American Journal of Obstetrics and Gynecology, 01.01.2018.

Research output: Contribution to journalArticle

Barbour, LA, Scifres, C, Valent, AM, Friedman, JE, Buchanan, TA, Coustan, D, Aagaard, K, Thornburg, KL, Catalano, PM, Galan, HL, Hay, WW, Frias, AE, Shankar, K, Simmons, RA, Moses, RG, Sacks, DA & Loeken, MR 2018, 'A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes' American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2018.06.013
Barbour, Linda A. ; Scifres, Christina ; Valent, Amy M. ; Friedman, Jacob E. ; Buchanan, Thomas A. ; Coustan, Donald ; Aagaard, Kjersti ; Thornburg, Kent L. ; Catalano, Patrick M. ; Galan, Henry L. ; Hay, William W. ; Frias, Antonio E. ; Shankar, Kartik ; Simmons, Rebecca A. ; Moses, Robert G. ; Sacks, David A. ; Loeken, Mary R. / A cautionary response to SMFM statement : pharmacological treatment of gestational diabetes. In: American Journal of Obstetrics and Gynecology. 2018.
@article{cc58c30a35dd4bb1ad208599ca745007,
title = "A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes",
abstract = "Use of oral agents to treat gestational diabetes mellitus remains controversial. Recent recommendations from the Society for Maternal-Fetal Medicine assert that metformin may be a safe first-line alternative to insulin for gestational diabetes mellitus treatment and preferable to glyburide. However, several issues should give pause to the widespread adoption of metformin use during pregnancy. Fetal concentrations of metformin are equal to maternal, and metformin can inhibit growth, suppress mitochondrial respiration, have epigenetic modifications on gene expression, mimic fetal nutrient restriction, and alter postnatal gluconeogenic responses. Because both the placenta and fetus express metformin transporters and exhibit high mitochondrial activity, these properties raise important questions about developmental programming of metabolic disease in offspring. Animal studies have demonstrated that prenatal metformin exposure results in adverse long-term outcomes on body weight and metabolism. Two recent clinical randomized controlled trials in women with gestational diabetes mellitus or polycystic ovary syndrome provide evidence that metformin exposure in utero may produce a metabolic phenotype that increases childhood weight or obesity. These developmental programming effects challenge the conclusion that metformin is equivalent to insulin. Although the Society for Maternal-Fetal Medicine statement endorsed metformin over glyburide if oral agents are used, there are few studies directly comparing the 2 agents and it is not clear that metformin alone is superior to glyburide. Moreover, it should be noted that prior clinical studies have dosed glyburide in a manner inconsistent with its pharmacokinetic properties, resulting in poor glycemic control and high rates of maternal hypoglycemia. We concur with the American Diabetes Association and American Congress of Obstetricians and Gynecologists, which recommend insulin as the preferred agent, but we believe that it is premature to embrace metformin as equivalent to insulin or superior to glyburide. Due to the uncertainty of the long-term metabolic risks of either metformin or glyburide, we call for carefully controlled studies that optimize oral medication dosing according to their pharmacodynamic and pharmacokinetic properties in pregnancy, appropriately target medications based on individual patterns of hyperglycemia, and follow the offspring long-term for metabolic risk.",
keywords = "diabetes in pregnancy, glyburide, guidelines, metformin",
author = "Barbour, {Linda A.} and Christina Scifres and Valent, {Amy M.} and Friedman, {Jacob E.} and Buchanan, {Thomas A.} and Donald Coustan and Kjersti Aagaard and Thornburg, {Kent L.} and Catalano, {Patrick M.} and Galan, {Henry L.} and Hay, {William W.} and Frias, {Antonio E.} and Kartik Shankar and Simmons, {Rebecca A.} and Moses, {Robert G.} and Sacks, {David A.} and Loeken, {Mary R.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ajog.2018.06.013",
language = "English (US)",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - A cautionary response to SMFM statement

T2 - American Journal of Obstetrics and Gynecology

AU - Barbour, Linda A.

AU - Scifres, Christina

AU - Valent, Amy M.

AU - Friedman, Jacob E.

AU - Buchanan, Thomas A.

AU - Coustan, Donald

AU - Aagaard, Kjersti

AU - Thornburg, Kent L.

AU - Catalano, Patrick M.

AU - Galan, Henry L.

AU - Hay, William W.

AU - Frias, Antonio E.

AU - Shankar, Kartik

AU - Simmons, Rebecca A.

AU - Moses, Robert G.

AU - Sacks, David A.

AU - Loeken, Mary R.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Use of oral agents to treat gestational diabetes mellitus remains controversial. Recent recommendations from the Society for Maternal-Fetal Medicine assert that metformin may be a safe first-line alternative to insulin for gestational diabetes mellitus treatment and preferable to glyburide. However, several issues should give pause to the widespread adoption of metformin use during pregnancy. Fetal concentrations of metformin are equal to maternal, and metformin can inhibit growth, suppress mitochondrial respiration, have epigenetic modifications on gene expression, mimic fetal nutrient restriction, and alter postnatal gluconeogenic responses. Because both the placenta and fetus express metformin transporters and exhibit high mitochondrial activity, these properties raise important questions about developmental programming of metabolic disease in offspring. Animal studies have demonstrated that prenatal metformin exposure results in adverse long-term outcomes on body weight and metabolism. Two recent clinical randomized controlled trials in women with gestational diabetes mellitus or polycystic ovary syndrome provide evidence that metformin exposure in utero may produce a metabolic phenotype that increases childhood weight or obesity. These developmental programming effects challenge the conclusion that metformin is equivalent to insulin. Although the Society for Maternal-Fetal Medicine statement endorsed metformin over glyburide if oral agents are used, there are few studies directly comparing the 2 agents and it is not clear that metformin alone is superior to glyburide. Moreover, it should be noted that prior clinical studies have dosed glyburide in a manner inconsistent with its pharmacokinetic properties, resulting in poor glycemic control and high rates of maternal hypoglycemia. We concur with the American Diabetes Association and American Congress of Obstetricians and Gynecologists, which recommend insulin as the preferred agent, but we believe that it is premature to embrace metformin as equivalent to insulin or superior to glyburide. Due to the uncertainty of the long-term metabolic risks of either metformin or glyburide, we call for carefully controlled studies that optimize oral medication dosing according to their pharmacodynamic and pharmacokinetic properties in pregnancy, appropriately target medications based on individual patterns of hyperglycemia, and follow the offspring long-term for metabolic risk.

AB - Use of oral agents to treat gestational diabetes mellitus remains controversial. Recent recommendations from the Society for Maternal-Fetal Medicine assert that metformin may be a safe first-line alternative to insulin for gestational diabetes mellitus treatment and preferable to glyburide. However, several issues should give pause to the widespread adoption of metformin use during pregnancy. Fetal concentrations of metformin are equal to maternal, and metformin can inhibit growth, suppress mitochondrial respiration, have epigenetic modifications on gene expression, mimic fetal nutrient restriction, and alter postnatal gluconeogenic responses. Because both the placenta and fetus express metformin transporters and exhibit high mitochondrial activity, these properties raise important questions about developmental programming of metabolic disease in offspring. Animal studies have demonstrated that prenatal metformin exposure results in adverse long-term outcomes on body weight and metabolism. Two recent clinical randomized controlled trials in women with gestational diabetes mellitus or polycystic ovary syndrome provide evidence that metformin exposure in utero may produce a metabolic phenotype that increases childhood weight or obesity. These developmental programming effects challenge the conclusion that metformin is equivalent to insulin. Although the Society for Maternal-Fetal Medicine statement endorsed metformin over glyburide if oral agents are used, there are few studies directly comparing the 2 agents and it is not clear that metformin alone is superior to glyburide. Moreover, it should be noted that prior clinical studies have dosed glyburide in a manner inconsistent with its pharmacokinetic properties, resulting in poor glycemic control and high rates of maternal hypoglycemia. We concur with the American Diabetes Association and American Congress of Obstetricians and Gynecologists, which recommend insulin as the preferred agent, but we believe that it is premature to embrace metformin as equivalent to insulin or superior to glyburide. Due to the uncertainty of the long-term metabolic risks of either metformin or glyburide, we call for carefully controlled studies that optimize oral medication dosing according to their pharmacodynamic and pharmacokinetic properties in pregnancy, appropriately target medications based on individual patterns of hyperglycemia, and follow the offspring long-term for metabolic risk.

KW - diabetes in pregnancy

KW - glyburide

KW - guidelines

KW - metformin

UR - http://www.scopus.com/inward/record.url?scp=85050621603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050621603&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2018.06.013

DO - 10.1016/j.ajog.2018.06.013

M3 - Article

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

ER -